Citations

Showing 10 of 108162 citations.

Teaching NeuroImages: Transependymal Oozing of Intrathecal Contrast Mimicking Intracerebral Hemorrhage
Neth, Bryan J. , Braksick, Sherri A. , Wijdicks, Eelco F. M. , Mustafa, Rafid , Wijdicks, Eelco Fm , Neth, Byran J.

Mayo Clinic

Neurology | January 27, 2021 | Volume: 96 | Issue: 22 | Pages: No page available

10.1212/wnl.0000000000011546 | PMID 33504637 Get It

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline
Daly, Megan E. , Ismaila, Nofisat , Decker, Roy H. , Owen, Dawn , Saxena, Ashish , Franklin, Gregg E., Donaldson, Dusty, Schneider, Bryan J. , Higgins, Kristin Ann

Mayo Clinic

Journal of Clinical Oncology | January 27, 2021 | Volume: 39 | Issue: 8 | Pages: 931-939

10.1200/jco.20.03364 | PMID 33502911 Get It

PURPOSE The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy (RT) for small-cell lung cancer (SCLC). Because of the relevance of this topic to ASCO membership, ASCO reviewed the guideline, applying a set of procedures and policies used to critically examine guidelines developed by other organizations. METHODS The ASTRO guideline on RT for SCLC was reviewed for developmental rigor by methodologists. Then, an ASCO Expert Panel reviewed the content and the recommendations. RESULTS The ASCO Expert Panel determined that the recommendations from ASTRO guideline on RT for SCLC, published in June 2020, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed ASTRO guideline on RT for SCLC with a few discussion points. RECOMMENDATIONS Recommendations addressed thoracic radiotherapy for limited-stage SCLC, role of stereotactic body radiotherapy in stage I or II node-negative SCLC, prophylactic cranial radiotherapy, and thoracic consolidation for extensive-stage SCLC. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
Association of AM-PAC “6-Clicks” Basic Mobility and Daily Activity Scores With Discharge Destination
Warren, Meghan , Knecht, Jeff, Verheijde, Joseph L., Tompkins, James, Verheijde, Joseph

Mayo Clinic

Physical Therapy | January 27, 2021 | Volume: 101 | Issue: 4 | Pages: No page available

10.1093/ptj/pzab043 | PMID 33517463 Get It

Abstract Objective The objective was to use the Activity Measure for Post-Acute Care “6-Clicks” scores at initial physical therapist and/or occupational therapist evaluation to assess (1) predictive ability for community versus institutional discharge, and (2) association with discharge destination (home/self-care [HOME], home health [HHA], skilled nursing facility [SNF], and inpatient rehabilitation facility [IRF]). Methods In this retrospective cohort study, initial “6-Clicks” Basic Mobility and/or Daily Activity t scores and discharge destination were obtained from electronic health records of 17,546 inpatient admissions receiving physical therapy/occupational therapy at an academic hospital between October 1, 2015 and August 31, 2018. For objective (1), postacute discharge destination was dichotomized to community (HOME and HHA) and institution (SNF and IRF). Receiver operator characteristic curves determined the most predictive Basic Mobility and Daily Activity scores for discharge destination. For objective (2), adjusted odds ratios (OR) from multinomial logistic regression assessed association between discharge destination (HOME, HHA, SNF, IRF) and cut-point scores for Basic Mobility (≤40.78 vs >40.78) and Daily Activity (≤40.22 vs >40.22), accounting for patient and clinical characteristics. Results Area under the curve for Basic Mobility was 0.80 (95% CI = 0.80–0.81) and Daily Activity was 0.81 (95% CI = 0.80–0.82). The best cut-point for Basic Mobility was 40.78 (raw score = 16; sensitivity = 0.71 and specificity = 0.74) and for Daily Activity was 40.22 (raw score = 19; sensitivity = 0.68 and specificity = 0.79). Basic Mobility and Daily Activity were significantly associated with discharge destination, with those above the cut-point resulting in increased odds of discharge HOME. The Basic Mobility scores ≤40.78 had higher odds of discharge to HHA (OR = 1.7 [95% CI = 1.5–1.9]), SNF (OR = 7.8 [95% CI = 6.8–8.9]), and IRF (OR = 7.5 [95% CI = 6.3–9.1]), and the Daily Activity scores ≤40.22 had higher odds of discharge to HHA (OR = 1.8 [95% CI = 1.7–2.0]), SNF (OR = 8.9 [95% CI = 7.9–10.0]), and IRF (OR = 11.4 [95% CI = 9.7–13.5]). Conclusion 6-Clicks at physical therapist/occupational therapist initial evaluation demonstrated good prediction for discharge decisions. Higher scores were associated with discharge to HOME; lower scores reflected discharge to settings with increased support levels. Impact Initial Basic Mobility and Daily Activity scores are valuable clinical tools in the determination of discharge destination.
Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib
Smith, Shane , Clark, Melanie A., Harker-Murray, Amy, Sokumbi, Olayemi , Sokumbi, Olayemi , Clarke, Callisia N.

Mayo Clinic

The American Journal of Dermatopathology | January 27, 2021 | Volume: 43 | Issue: 8 | Pages: 585-587

10.1097/dad.0000000000001849 | PMID 33534208 Get It

Abstract: Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.
Progress toward the Clinical Application of Mesenchymal Stromal Cells and Other Disease-Modulating Regenerative Therapies: Examples from the Field of Nephrology
Hickson, LaTonya J. , McNicholas, Bairbre , Griffin, Matthew D. , Griffin, Matthew D , Hickson, LaTonya J , Herrmann, Sandra M.

Mayo Clinic

Kidney360 | January 27, 2021 | Volume: 2 | Issue: 3 | Pages: 542-557

10.34067/kid.0005692020 | PMID 34316720 Get It

Drawing from basic knowledge of stem-cell biology, embryonic development, wound healing, and aging, regenerative medicine seeks to develop therapeutic strategies that complement or replace conventional treatments by actively repairing diseased tissue or generating new organs and tissues. Among the various clinical-translational strategies within the field of regenerative medicine, several can be broadly described as promoting disease resolution indirectly through local or systemic interactions with a patient’s cells, without permanently integrating or directly forming new primary tissue. In this review, we focus on such therapies, which we term disease-modulating regenerative therapies (DMRT), and on the extent to which they have been translated into the clinical arena in four distinct areas of nephrology: renovascular disease (RVD), sepsis-associated AKI (SA-AKI), diabetic kidney disease (DKD), and kidney transplantation (KTx). As we describe, the DMRT that has most consistently progressed to human clinical trials for these indications is mesenchymal stem/stromal cells (MSCs), which potently modulate ischemic, inflammatory, profibrotic, and immune-mediated tissue injury through diverse paracrine mechanisms. In KTx, several early-phase clinical trials have also tested the potential for ex vivo –expanded regulatory immune cell therapies to promote donor-specific tolerance and prevent or resolve allograft injury. Other promising DMRT, including adult stem/progenitor cells, stem cell–derived extracellular vesicles, and implantable hydrogels/biomaterials remain at varying preclinical stages of translation for these renal conditions. To date (2021), no DMRT has gained market approval for use in patients with RVD, SA-AKI, DKD, or KTx, and clinical trials demonstrating definitive, cost-effective patient benefits are needed. Nonetheless, exciting progress in understanding the disease-specific mechanisms of action of MSCs and other DMRT, coupled with increasing knowledge of the pathophysiologic basis for renal-tissue injury and the experience gained from pioneering early-phase clinical trials provide optimism that influential, regenerative treatments for diverse kidney diseases will emerge in the years ahead.
Effect of Partial Uncinectomy After Balloon Sinuplasty on Maxillary Sinus Irrigant Penetration: A Cadaveric Study
Karataylι-Özgürsoy, Selmin, Gonzalez, Valeria , Olomu, Osarenoma , Donaldson, Angela M. , Martinez-Paredes, Jhon F, Karatayli-Ozgursoy, Selmin, Gonzalez, Valeria V , Martinez‐Paredes, Jhon F.

Mayo Clinic

OTO Open | January 27, 2021 | Volume: 5 | Issue: 1 | Pages: No page available

10.1177/2473974x21989583 | PMID 33598598 Get It

ObjectiveThe uncinate process may play a role in the amount of irrigation penetrance. In this cadaver study, we aimed to investigate if the addition of partial uncinectomy provides better maxillary sinus irrigation penetrance than balloon sinuplasty (BSP) alone.Study DesignCadaveric study.SettingSimulation laboratory at the Mayo Clinic in Florida.MethodsFive fresh‐frozen human cadaveric heads (10 sides) were used to assess maxillary sinus irrigation penetration after 3 interventions performed sequentially: irrigation penetrance with no intervention, irrigation after BSP, and irrigation after BSP and partial removal of the uncinate. Penetrance was recorded with intrasinus endoscopy and scored by 4 blinded observers using a scale from 0 (no irrigation) to 5 (fully irrigated). The diameter of the maxillary ostium was measured before and after BSP. Internal consistency was evaluated with Cronbach’s alpha.ResultsMean ostium size increased from 4.1 to 6.8 mm after BSP (P =. 013). Cronbach’s alpha was 0.93. The median scores of irrigation penetration after no intervention, BSP, and BSP and partial uncinectomy were 2.5, 3, and 4, respectively. We found a significantly higher penetrance following partial uncinectomy plus BSP versus BSP alone (P =. 008). Both interventions had a statistically significant difference in irrigation penetrance as compared with no intervention (P =. 0001).ConclusionMaxillary sinus irrigation penetration increased from baseline after BSP. The addition of a partial uncinectomy to the balloon dilation of the maxillary sinus was associated with a statistically significant increase in irrigation penetrance scores as compared with BSP alone.
Using machine learning to improve the accuracy of patient deterioration predictions: Mayo Clinic Early Warning Score (MC-EWS)
Romero‐Brufau, Santiago , Whitford, Daniel , Johnson, Matthew G. , Hickman, Joel , Morlan, Bruce W., Therneau, Terry M. , Naessens, James M. , Naessens, James , Romero-Brufau, Santiago , Huddleston, Jeanne M.

Mayo Clinic

Journal of the American Medical Informatics Association | January 27, 2021 | Volume: 28 | Issue: 6 | Pages: 1207-1215

10.1093/jamia/ocaa347 | PMID 33638343 Get It

Abstract Objective We aimed to develop a model for accurate prediction of general care inpatient deterioration. Materials and Methods Training and internal validation datasets were built using 2-year data from a quaternary hospital in the Midwest. Model training used gradient boosting and feature engineering (clinically relevant interactions, time-series information) to predict general care inpatient deterioration (resuscitation call, intensive care unit transfer, or rapid response team call) in 24 hours. Data from a tertiary care hospital in the Southwest were used for external validation. C-statistic, sensitivity, positive predictive value, and alert rate were calculated for different cutoffs and compared with the National Early Warning Score. Sensitivity analysis evaluated prediction of intensive care unit transfer or resuscitation call. Results Training, internal validation, and external validation datasets included 24 500, 25 784 and 53 956 hospitalizations, respectively. The Mayo Clinic Early Warning Score (MC-EWS) demonstrated excellent discrimination in both the internal and external validation datasets (C-statistic = 0.913, 0.937, respectively), and results were consistent in the sensitivity analysis (C-statistic = 0.932 in external validation). At a sensitivity of 73%, MC-EWS would generate 0.7 alerts per day per 10 patients, 45% less than the National Early Warning Score. Discussion Low alert rates are important for implementation of an alert system. Other early warning scores developed for the general care ward have achieved lower discrimination overall compared with MC-EWS, likely because MC-EWS includes both nursing assessments and extensive feature engineering. Conclusions MC-EWS achieved superior prediction of general care inpatient deterioration using sophisticated feature engineering and a machine learning approach, reducing alert rate.
30‐day patient reported outcomes can be predicted by change in left atrial pressure and not change in transmitral gradient following MitraClip
Pierre, Keniel , Adedinsewo, Demilade , Miranda, William R. , Eleid, Mackram F. , Pollak, Peter , Rihal, Charanjit S. , Sabbagh, Abdallah El , Adedinsewo, Demilade A , Al-Hijji, Mohammed, Miranda, William R , Eleid, Mackram F , Pollak, Peter M, El Sabbagh, Abdallah , Al‐Hijji, Mohammed , Alkhouli, Mohamad , Guerrero, Mayra , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 27, 2021 | Volume: 97 | Issue: 6 | Pages: 1244-1249

10.1002/ccd.29477 | PMID 33502087 Get It

AbstractBackgroundChange in left atrial pressure (LAP) has been shown to be associated with symptom improvement post‐MitraClip; however, the association between acute procedural changes in transmitral diastolic mean gradient (MG) compared to LAP and symptom improvement is not well established.Methods164 consecutive patients undergoing MitraClip at Mayo Clinic between June 2014 and May 2018 were included. Preclip and postclip MG and LAP were recorded. Baseline demographics, clinical, and echocardiographic outcomes, including 30‐day New York Heart Association (NYHA) functional status were obtained from patient charts.ResultsMedian age was 81.5 years (IQR: 76.3, 87), 34% were female and 94.5% had NYHA class III and IV functional status at baseline. At baseline, median MG was 4 mmHg (IQR: 3, 5) and LAP was 19 mmHg (IQR: 16, 23.5). Following MitraClip deployment, the median MG was 4 mmHg (IQR: 3, 6) and the median LAP was 17 mmHg (IQR: 14, 21), 69.5% of patients had less than moderate MR. There was no statistically significant association between change in MG and NYHA functional class at 30 days (OR = 0.95, 95% CI: 0.76–1.20). However, a reduction in LAP following MitraClip deployment was significantly associated with improvement in NYHA functional status at 30 days following adjustments for age and sex (aOR 3.36, 95% CI: 1.34–8.65). There was no significant correlation between change in mean LAP and change in MG (p = .98).ConclusionUnlike change in left atrial pressure, change in MG post‐MitraClip was not associated with patient reported outcomes at 30 days and did not correlate with change in left atrial pressure. Long‐term follow up is needed to evaluate the impact of LA pressure on symptoms.
Localized Vasculitis of the Gastrointestinal Tract
Kamboj, Amrit K. , Benanzer, Tessa M., Sweetser, Seth

Mayo Clinic

American Journal of Gastroenterology | January 27, 2021 | Volume: 116 | Issue: 9 | Pages: 1823-1823

10.14309/ajg.0000000000001169 | PMID 34465688 Get It

In from the cold: M‐protein light chain glycosylation is positively associated with cold agglutinin titer levels
Juskewitch, Justin E. , Murray, Josiah , Norgan, Andrew P. , Moldenhauer, Sheila K., Tauscher, Craig D. , Jacob, Eapen K., Murray, David , Murray, Josiah D , Murray, David L., Norgan, Andrew P , Juskewitch, Justin E

Mayo Clinic

Transfusion | January 27, 2021 | Volume: 61 | Issue: 4 | Pages: 1302-1311

10.1111/trf.16279 | PMID 33502021 Get It

AbstractBackgroundPrimary cold agglutinin disease (CAD) is a monoclonal antibody (M‐protein) and complement‐mediated chronic hemolytic disease process. Antibody glycosylation can play a role in both antibody half‐life and complement fixation. Recently, M‐protein light chain (LC) glycosylation has been shown to be associated with AL amyloidosis. We hypothesized that M‐protein LC glycosylation is also associated with cold agglutinin (CA) titers and CA‐mediated hemolysis.Study Design and MethodsA cross‐sectional study of patients undergoing CA titer evaluation underwent mass spectrometric analysis for M‐proteins and M‐protein LC glycosylation. A subset of serum samples also underwent evaluation for the ability to trigger cold hemolysis in vitro. M‐protein and M‐protein LC glycosylation rates were compared across CA titer groups, clinical diagnosis, direct antiglobulin testing (DAT) results, and cold in vitro hemolysis rates.ResultsBoth M‐protein and M‐protein LC glycosylation rates significantly differed across CA titer groups with the highest rates in those with elevated CA titers. M‐protein LC glycosylation occurred almost exclusively on IgM kappa M‐proteins and was significantly associated with positive DAT results and a clinical diagnosis of CAD. Cold in vitro hemolysis was demonstrated in two patients who both had a CA titer of more than 512 but there was no significant association with CA titer group or M‐protein LC glycosylation status.ConclusionM‐protein LC glycosylation is significantly associated with higher CA titer levels. Given the role that antibody glycosylation can play in antibody half‐life and complement fixation, further studies are needed to clarify the effects of LC glycosylation within the context of CAD.